Learn more

TRANSITION THERAPEUTICS INC

Overview
  • Total Patents
    36
About

TRANSITION THERAPEUTICS INC has a total of 36 patent applications. Its first patent ever was published in 1998. It filed its patents most often in United States, EPO (European Patent Office) and Canada. Its main competitors in its focus markets pharmaceuticals, biotechnology and environmental technology are UNIV CONNECTICUT HEALTH CT, UNIV OF CONNECTICUT HEALTH CENTER and SYNERGY PHARMACEUTICALS INC.

Patent filings per year

Chart showing TRANSITION THERAPEUTICS INCs patent filings per year from 1900 to 2020

Top inventors

# Name Total Patents
#1 Pastrak Aleksandra 21
#2 Cruz Tony 21
#3 Nestor John 7
#4 Turley Eva A 6
#5 Cruz Antonio 4
#6 Kuhns William 2
#7 Cruz Tony F 2
#8 Pristupa Zdenek 2
#9 Nestor Jr John J 1
#10 Schriemer David C 1

Latest patents

Publication Filing date Title
US2009170775A1 Vasoactive intestinal polypeptide compositions
US2006234933A1 Vasoactive intestinal polypeptide pharmaceuticals
EP1793846A1 Compositions and methods comprising vitamin b12 and an impdh inhibitor for treating viral, inflammatory and proliferative diseases
WO2005094842A1 Vitamin b12-containing compositions and methods of use
US2005175585A1 Combination therapies using vitamin B12 and interferon for treatment of viral proliferative and inflammatory disesases
WO03040368A2 Pharmaceutical compositions of marine sponge microciona prolifera
WO03030929A1 Combination therapies using methyl donors or methyl donor enhancers and therapeutic agents for treatment of viral, proliferative and inflammatory diseases
US2003027863A1 Use of rhein or diacerhein compounds for the treatment or prevention of vascular diseases
CA2487038A1 Combination therapies using vitamin b12 and therapeutic agents for treatment of viral, proliferative and inflammatory diseases
US6911429B2 Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
EP1324765A1 Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans